SAN DIEGO--(BUSINESS WIRE)--Batu Biologics announced today that its President and CEO, Samuel Wagner, was interviewed by CEOCFO Magazine, a weekly industry publication that conducts in depth interviews with corporate executives.
The interview highlighted ValloVax™, a novel cancer vaccine developed by Batu Biologics which trains the immune system to selectively kill the blood vessels that feed the tumor. Preclinical data supports the initial clinical trial of ValloVax™ to be conducted for the condition of lung cancer. The interview is available online at: http://webmail.ceocfointerviews.com/interviews/BatuBiologics14.htm.
Currently, Batu Biologics is raising funds to accelerate FDA development of its lung cancer vaccine through a donation-based crowdfunding campaign, which may be viewed at the following link: https://www.indiegogo.com/projects/emerging-lung-cancer-vaccine-targets-tumor-blood-vessels-introducing-vallovax/x/7953725.
“We are pleased with the Internet attention that has been generated by the launch of our crowdfunding campaign, and today’s interview is one example of this,” said Samuel Wagner, President and CEO of Batu Biologics. “Given the devastation that lung cancer causes on society and the apparent lack of non-toxic approaches to this condition, we are pleased with the interest garnished by public media. There is a fundamental lack of knowledge regarding lung cancer in the eyes of the public and various governmental decision makers. More attention to this cause will benefit not only Batu Biologics, but also the numerous researchers dedicated to making an impact in this terrible disease.”
According to the American Lung Association, lung cancer is the leading cancer killer in both men and women in the United States. Furthermore, lung cancer causes more deaths than the next three most common cancers combined (colon, breast and pancreatic). It is estimated that in the US alone, lung cancer care costs are $14 billion per year.
“Given that the majority of lung cancers are diagnosed late in progression, the majority of patients have limited treatment options, which often carry a heavy burden of toxicity,” said Dr. Thomas Ichim, Executive Chairman of Batu Biologics. “Targeting blood vessels that feed cancers has led to the blockbuster success of the drug Avastin, however, this agent only blocks one of the pathways (the VEGF pathway) associated with tumor blood vessel growth. Our current data suggests that ValloVax™ stimulates the immune system to block multiple biological pathways necessary for angiogenesis, thus having the potential for superior efficacy as compared to existing drugs.”
About Batu Biologics: Batu Biologics is a biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area of immune modulation. Our products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its two flagship products: Immstem and Vallovax. Batu Biologics has filed two provisional patents in the field of cancer immunotherapy and plans to significantly expand its IP in 2014. Recently, Batu Biologics published in the peer reviewed literature with Dr. Francesco Marincola, President of the Society for Immunotherapy of Cancer, as well as several other internationally-renowned immunotherapists, a novel method of decreasing toxicity of immunotherapy http://www.translational-medicine.com/content/pdf/1479-5876-12-127.pdf
9255 Towne Centre Drive
San Diego, CA 92121
Janssen Research and Development
3210 Merryfield Row
San Diego, CA 92121